FI990991A0 - Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi - Google Patents

Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi

Info

Publication number
FI990991A0
FI990991A0 FI990991A FI990991A FI990991A0 FI 990991 A0 FI990991 A0 FI 990991A0 FI 990991 A FI990991 A FI 990991A FI 990991 A FI990991 A FI 990991A FI 990991 A0 FI990991 A0 FI 990991A0
Authority
FI
Finland
Prior art keywords
individual
analyte
identifying
risk
neurological damage
Prior art date
Application number
FI990991A
Other languages
English (en)
Swedish (sv)
Other versions
FI990991A (fi
Original Assignee
Locus Genex Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Genex Oy filed Critical Locus Genex Oy
Priority to FI990991A priority Critical patent/FI990991A/fi
Publication of FI990991A0 publication Critical patent/FI990991A0/fi
Priority to ES00922683T priority patent/ES2258453T3/es
Priority to PT00922683T priority patent/PT1173764E/pt
Priority to PCT/FI2000/000376 priority patent/WO2000067029A1/en
Priority to DK00922683T priority patent/DK1173764T3/da
Priority to DE60026285T priority patent/DE60026285T2/de
Priority to CN00808519A priority patent/CN1353816A/zh
Priority to AU42997/00A priority patent/AU4299700A/en
Priority to EP00922683A priority patent/EP1173764B1/en
Priority to RU2001132334/15A priority patent/RU2224258C2/ru
Priority to JP2000615816A priority patent/JP2002543430A/ja
Priority to AT00922683T priority patent/ATE319088T1/de
Publication of FI990991A publication Critical patent/FI990991A/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
FI990991A 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi FI990991A (fi)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FI990991A FI990991A (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi
AT00922683T ATE319088T1 (de) 1999-04-30 2000-04-28 Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst
DK00922683T DK1173764T3 (da) 1999-04-30 2000-04-28 Fremgangsmåde til identifikation af et individ med risiko for irreversible neuroskader, omfattende trinnene kvantitativ bestemmelse af koncentrationen af pepsinogen I (PGI) og vitamin B12
PT00922683T PT1173764E (pt) 1999-04-30 2000-04-28 Metodo para identificar um individuo em perigo de danos neurologicos irreversiveis, compreendendo os passos de determinar quantitativamente a concentracao de pepsinogenio i (pgi) e vitamina b12
PCT/FI2000/000376 WO2000067029A1 (en) 1999-04-30 2000-04-28 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12
ES00922683T ES2258453T3 (es) 1999-04-30 2000-04-28 Metodo para identificar un individuo con riesgo de daños neurologicos irreversibles, que comprende las etapas de determinacion cuantitativa de la concentracion de pepsinogeno (i) y vitamina b12.
DE60026285T DE60026285T2 (de) 1999-04-30 2000-04-28 Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst
CN00808519A CN1353816A (zh) 1999-04-30 2000-04-28 不可逆性神经损伤易感个体的鉴定方法,包括定量检测胃蛋白酶原i(pgi)和维生素b12浓度的步骤
AU42997/00A AU4299700A (en) 1999-04-30 2000-04-28 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i(pgi) and vitamin b12
EP00922683A EP1173764B1 (en) 1999-04-30 2000-04-28 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12
RU2001132334/15A RU2224258C2 (ru) 1999-04-30 2000-04-28 Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12
JP2000615816A JP2002543430A (ja) 1999-04-30 2000-04-28 ペプシノーゲンｉ（ｐｇｉ）及びビタミンｂ１２の濃度を定量的に測定するステップを含む、不可逆的な神経障害の危険性のある人を同定する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI990991A FI990991A (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi

Publications (2)

Publication Number Publication Date
FI990991A0 true FI990991A0 (fi) 1999-04-30
FI990991A FI990991A (fi) 2000-10-31

Family

ID=8554566

Family Applications (1)

Application Number Title Priority Date Filing Date
FI990991A FI990991A (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi

Country Status (12)

Country Link
EP (1) EP1173764B1 (fi)
JP (1) JP2002543430A (fi)
CN (1) CN1353816A (fi)
AT (1) ATE319088T1 (fi)
AU (1) AU4299700A (fi)
DE (1) DE60026285T2 (fi)
DK (1) DK1173764T3 (fi)
ES (1) ES2258453T3 (fi)
FI (1) FI990991A (fi)
PT (1) PT1173764E (fi)
RU (1) RU2224258C2 (fi)
WO (1) WO2000067029A1 (fi)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019A (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
FI20065542A0 (fi) * 2006-09-01 2006-09-01 Biohit Oyj Menetelmä ja näytteenottopakkaus vatsan limakalvon tilan arvioimiseksi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97304C (fi) * 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi

Also Published As

Publication number Publication date
PT1173764E (pt) 2006-06-30
DK1173764T3 (da) 2006-05-08
AU4299700A (en) 2000-11-17
FI990991A (fi) 2000-10-31
DE60026285T2 (de) 2006-11-09
RU2224258C2 (ru) 2004-02-20
JP2002543430A (ja) 2002-12-17
CN1353816A (zh) 2002-06-12
EP1173764A1 (en) 2002-01-23
DE60026285D1 (de) 2006-04-27
ES2258453T3 (es) 2006-09-01
WO2000067029A1 (en) 2000-11-09
EP1173764B1 (en) 2006-03-01
ATE319088T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
WO2003056314A3 (de) Analysensystem zur bestimmung einer analytkonzentration unter berücksichtigung von proben- und analytunabhängigen lichtintensitätsänderungen
DK0539477T3 (da) Fremgangsmåde til forstærkning af emissionssignalet af en luminescerende forbindelse
ES2316597T8 (es) Instrumentos analíticos, biosensores y métodos
DK1098658T3 (da) Manipulerede proteiner til detektering af analytter
DK0988534T3 (da) Elektroniske fremgangsmåder og apparat til detektering af analytter
ES8802618A1 (es) Procedimiento para la purificacion de proteina amilaide a desuero (saa)
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
FI990992A0 (fi) Menetelmä peptisen haavan riskin määrittämiseksi
ATE232559T1 (de) Verfahren zur signalverstärkung
ATE353138T1 (de) Verfahren zur stabilisierung und messung von troponinkomplexen
ATE509119T1 (de) Verfahren zum testen von glykosyliertem protein
ATE545460T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
DE60310012D1 (de) Verfahren, Assay und Kit zur Quantifizierung von HIV-Proteasehemmer
DE602004027129D1 (de) Verfahren und vorrichtung zum nachweis flüchtiger analyten in luftproben
ATE333510T1 (de) Enzymatische messung von mycophenolsäure
ATE469241T1 (de) Verfahren zur vorbehandlung von proben zur bestimmung von verzuckerten aminen, sowie verfahren zur bestimmung von verzuckerten aminen
ATE285581T1 (de) Assay-verfahren
DK1104547T3 (da) In vitro-fremgangsmåde til påvisning og diagnosticering af akutte koronarsyndromer
FI990991A0 (fi) Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi
AU2003260530A1 (en) Method for detecting a risk of acid related disease in an individual
DK1567661T3 (da) Fremgangsmåder, biosensorer og sæt til detektion og identificering af svampe
ATE248371T1 (de) Allergennachweis
RU2001132334A (ru) Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12
DE69920981D1 (de) Knorpelresorptionsassays
DK1423708T3 (da) Sammensætninger og fremgangsmåder til bestemmelser af AA4RP